Amgevita is now broadly available across Canada.
Amgen Canada has launched its adalimumab biosimilar (Amgevita), referencing Humira. The biosimilar is available for all indications of the reference product. These include rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, and ulcerative colitis.
"We are pleased that Amgevita is now available in Canada, offering patients and physicians a treatment option and flexibility of choice in therapies they may not otherwise have," said Suna Avcil, executive medical director, Amgen Canada.
The company said Amgevita is now covered by public drug plans in the provinces of British Columbia, Alberta, Ontario, Quebec, New Brunswick, and Newfoundland. The biosimilar is available in prefilled syringe and prefilled pen forms.
Recently, Alberta expanded its biosimilar switching program to include adalimumab versions. Starting May 1, roughly 3300 patients currently prescribed Humira will switch to 1 of 5 adalimumab biosimilars. According to Biosimilars Canada, a trade group, adalimumab is one of the top selling biologics in Canada, where adalimumab biosimilars entered the market in February 2021. Alberta, British Columbia, and New Brunswick each have instituted switching policies to get patients started on lower cost biosimilar forms of adalimumab.
For more about Canada's biosimilar switching policies, click here.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Adalimumab Biosimilars Take Center Stage: A Game Changer for IBD Treatment
July 16th 2023Laura Wingate, from the Crohn's & Colitis Foundation, explains some of the challenges regarding educating patients and providers on biosimilars for inflammatory bowel disease (IBD) as well as whether the gastroenterology space is ready for the influx of adalimumab biosimilars.